Massachusetts Financial Services’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-20,202
| Closed | -$10.6M | – | 907 |
|
|
2025
Q2 | $10.6M | Sell |
20,202
-761
| -4% | -$425K | ﹤0.01% | 674 |
|
|
2025
Q1 | $13.3M | Buy |
20,963
+5,729
| +38% | +$3.94M | ﹤0.01% | 635 |
|
|
2024
Q4 | $10.9M | Sell |
15,234
-499,031
| -97% | -$419M | ﹤0.01% | 648 |
|
|
2024
Q3 | $541M | Sell |
514,265
-26,028
| -5% | -$29M | 0.16% | 155 |
|
|
2024
Q2 | $568M | Buy |
540,293
+59,769
| +12% | +$57.9M | 0.17% | 143 |
|
|
2024
Q1 | $462M | Buy |
480,524
+238,174
| +98% | +$226M | 0.14% | 162 |
|
|
2023
Q4 | $213M | Buy |
242,350
+6,879
| +3% | +$5.66M | 0.07% | 246 |
|
|
2023
Q3 | $194M | Sell |
235,471
-315,252
| -57% | -$248M | 0.07% | 243 |
|
|
2023
Q2 | $396M | Sell |
550,723
-803
| -0.1% | -$619K | 0.13% | 165 |
|
|
2023
Q1 | $453M | Buy |
551,526
+3,257
| +0.6% | +$2.46M | 0.16% | 153 |
|
|
2022
Q4 | $396M | Buy |
548,269
+349,860
| +176% | +$258M | 0.14% | 162 |
|
|
2022
Q3 | $137M | Buy |
+198,409
| New | +$125M | 0.05% | 283 |
|
|
2021
Q3 | – | Sell |
-2,650
| Closed | -$1.48M | – | 930 |
|
|
2021
Q2 | $1.48M | Sell |
2,650
-8,068
| -75% | -$4.09M | ﹤0.01% | 808 |
|
|
2021
Q1 | $5.07M | Sell |
10,718
-109
| -1% | -$53.1K | ﹤0.01% | 693 |
|
|
2020
Q4 | $5.23M | Sell |
10,827
-1,080
| -9% | -$583K | ﹤0.01% | 674 |
|
|
2020
Q3 | $6.67M | Buy |
11,907
+8,663
| +267% | +$5.25M | ﹤0.01% | 653 |
|
|
2020
Q2 | $2.02M | Sell |
3,244
-3,723
| -53% | -$2.11M | ﹤0.01% | 687 |
|
|
2020
Q1 | $3.4M | Sell |
6,967
-767
| -10% | -$316K | ﹤0.01% | 646 |
|
|
2019
Q4 | $2.9M | Sell |
7,734
-16,512
| -68% | -$5.56M | ﹤0.01% | 682 |
|
|
2019
Q3 | $6.72M | Sell |
24,246
-2,001
| -8% | -$592K | ﹤0.01% | 639 |
|
|
2019
Q2 | $8.22M | Sell |
26,247
-300,814
| -92% | -$100M | ﹤0.01% | 640 |
|
|
2019
Q1 | $134M | Buy |
327,061
+122,363
| +60% | +$50.4M | 0.06% | 239 |
|
|
2018
Q4 | $76.5M | Buy |
204,698
+29,457
| +17% | +$10.8M | 0.04% | 316 |
|
|
2018
Q3 | $70.8M | Sell |
175,241
-1,812
| -1% | -$690K | 0.03% | 346 |
|
|
2018
Q2 | $61.1M | Sell |
177,053
-133,671
| -43% | -$41.8M | 0.03% | 369 |
|
|
2018
Q1 | $107M | Sell |
310,724
-32,041
| -9% | -$11.1M | 0.05% | 265 |
|
|
2017
Q4 | $129M | Sell |
342,765
-159,333
| -32% | -$64.5M | 0.05% | 239 |
|
|
2017
Q3 | $224M | Buy |
502,098
+86,705
| +21% | +$41.3M | 0.1% | 181 |
|
|
2017
Q2 | $204M | Buy |
415,393
+113,894
| +38% | +$49.8M | 0.09% | 187 |
|
|
2017
Q1 | $117M | Buy |
301,499
+3,348
| +1% | +$1.24M | 0.05% | 236 |
|
|
2016
Q4 | $109M | Buy |
298,151
+6,777
| +2% | +$2.58M | 0.05% | 244 |
|
|
2016
Q3 | $117M | Buy |
291,374
+42,631
| +17% | +$17.1M | 0.06% | 233 |
|
|
2016
Q2 | $86.9M | Buy |
248,743
+38,003
| +18% | +$14.6M | 0.04% | 266 |
|
|
2016
Q1 | $76M | Sell |
210,740
-211,368
| -50% | -$87.1M | 0.04% | 276 |
|
|
2015
Q4 | $229M | Sell |
422,108
-21,559
| -5% | -$11.7M | 0.12% | 165 |
|
|
2015
Q3 | $206M | Sell |
443,667
-91,585
| -17% | -$49.2M | 0.12% | 169 |
|
|
2015
Q2 | $273M | Sell |
535,252
-23,912
| -4% | -$11.7M | 0.14% | 153 |
|
|
2015
Q1 | $252M | Sell |
559,164
-29,108
| -5% | -$12.3M | 0.13% | 164 |
|
|
2014
Q4 | $241M | Buy |
588,272
+21,340
| +4% | +$8.39M | 0.12% | 167 |
|
|
2014
Q3 | $204M | Buy |
566,932
+25,612
| +5% | +$8.58M | 0.11% | 176 |
|
|
2014
Q2 | $153M | Buy |
541,320
+147,253
| +37% | +$43.6M | 0.08% | 203 |
|
|
2014
Q1 | $118M | Buy |
394,067
+77,483
| +24% | +$23.9M | 0.06% | 230 |
|
|
2013
Q4 | $87.1M | Buy |
316,584
+4,247
| +1% | +$1.22M | 0.05% | 263 |
|
|
2013
Q3 | $97.7M | Buy |
312,337
+29,154
| +10% | +$7.67M | 0.06% | 244 |
|
|
2013
Q2 | $63.7M | Buy |
+283,183
| New | +$65.9M | 0.04% | 285 |
|
Other funds holding REGN
Massachusetts Financial Services's REGN Position: Q3 2025 in Review
Massachusetts Financial Services sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 20,202 shares — an estimated $10.6M sold.
Massachusetts Financial Services first reported a position in REGN in Q2 2013 and held it in 45 quarters. The position peaked at $568M in Q2 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.
- Massachusetts Financial Services reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
- Massachusetts Financial Services sold 20,202 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $10.6M.
- Massachusetts Financial Services first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 45 quarters.
- Massachusetts Financial Services's Regeneron Pharmaceuticals position peaked at $568M in Q2 2024.
- 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.
Based on Massachusetts Financial Services's 13F filing for Q3 2025, filed 29 Oct 2025.